STATResearch Highlights

STAT+: At AACR, Chinese Biotech, Oncology’s Comms Issue, and More

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and scope

This brief synthesizes the STAT News AACR pop-up newsletter excerpt provided.

It reports on highlights from Revolution Medicines’ presentations at the American Association for Cancer Research annual meeting as described in the source.

No additional studies, data, or external claims beyond the source content are introduced.

Main signal — an investigational RAS-targeting compound

Revolution Medicines presented clinical and mechanistic material that drew strong attendee interest.
The company discussed daraxonrasib data in frontline pancreatic cancer (not detailed in this excerpt) and introduced a newer agent, RM-055.

Mechanism described by the company

CEO Mark Goldsmith characterized RM-055 as belonging to a proposed class of “catalytic inhibitors.”
The described mechanism is enzymatic removal of a phosphate from GTP-bound RAS (the active form), thereby converting the protein to its inactive state.
The company framed this catalytic activity as enabling one molecule of RM-055 to inactivate multiple RAS proteins.

Rationale and potential advantage highlighted

The newsletter explains that a common route to resistance against existing RAS inhibitors is amplification of mutant RAS, which increases the cellular concentration of the active oncoprotein and can overwhelm stoichiometric inhibitors.
RM-055’s catalytic mechanism was presented as conceptually capable of addressing that resistance mechanism by inactivating multiple mutant RAS molecules rather than binding in a one-to-one fashion.

Limitations and missing details

Specific preclinical or clinical efficacy data, safety findings, dosing, study design, patient population, and statistical outcomes for RM-055 were not reported in the provided excerpt.
No independent corroboration or external expert commentary is included in the source text.